EUVIMEDEUVIMED entdecken
Crossref

Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey

Tatyana Kushner iD, Maria Buti, Mohamed El-Kassas iD, Yusuf Yilmaz iD, Hirokazu Takahashi, Yuichiro Eguchi iD, Stuart K Roberts, Wah-Kheong Chan, Ming-Lung Yu iD, Ponsiano Ocama, Saira Khaderi, Manida Wungjiranirun und 12 weitere

Liver International · 2026-05 · 46 (5)

DOI: 10.1111/liv.70619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 06.04.2026. Verfasst von Tatyana Kushner und 23 weiteren Autor:innen. Beteiligte Einrichtung: The Global Liver Council, Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Pregnancy Complications, Infectious, Hepatitis C, Practice Patterns, Physicians'. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Global NASH/MASH, Global Liver Council, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Although pregnant people are a WHO priority population for hepatitis C (HCV) elimination, there is limited guidance on HCV treatment in pregnancy. Emerging data suggests direct acting antiviral (DAA) therapy is safe and effective. We performed a multinational survey among gastro‐hepatologists (GI‐Hep), infectious disease (ID) specialists, obstetricians‐gynaecologists (ob‐gyns), and general practitioners (GP) to evaluate current perspectives on HCV treatment in pregnancy.

Methods

A 39‐item survey was designed by experts at The Global Liver Council, the American College of Obstetricians and Gynaecologists, and the Coalition for Global Hepatitis Elimination and distributed electronically. Survey responses were compared across medical specialties and regions.

Results

A total of 651 participants from all WHO regions representing 58 countries completed the survey: GI‐Hep: 46%, GP‐ID: 36%, ob‐gyns: 18%. Only 25% would consider treating HCV during pregnancy, with significant differences by specialty. Main reasons for not considering DAAs in pregnancy were insufficient safety data (27%) and no clear guidelines for HCV treatment (32%). The highest acceptance of DAA use in pregnancy was in North America (45% vs. < 20% in other regions ( p < 0.01)). Predictors of a greater willingness to treat HCV in pregnancy were having ≥ 10% of practice population with injection drug use (aOR: 2.31; 95% CI: 1.49–3.60; p = 0.0002). GI‐Hep specialty was associated with a lower willingness (aOR: 0.47; 95% CI: 0.28–0.78; p = 0.004).

Conclusions

Despite relatively high levels of HCV knowledge, few participants have experience with HCV treatment in pregnancy or would consider such treatment. Further availability of safety evidence and the inclusion of specific recommendations in guidelines could increase uptake of DAAs for pregnant individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsPregnancy Complications, InfectiousHepatitis CPractice Patterns, Physicians'Attitude of Health PersonnelHumansFemalePregnancySurveys and QuestionnairesObstetriciansGynecologistsAdultObstetricsGeneral Practitioners

Stichwörter der Autor:innen

direct‐acting antiviral safety in pregnancyperinatal outcomesuniversal screeningvertical transmission

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • The Global Liver Council, Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA.
  • Division of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, New York, USA.
  • Division of Obstetrics & Gynecology, Weill Cornell Medicine, New York, New York, USA.
  • Liver Unit, Hospital Universitari Vall d Hebron and CIBEREHD del Instituto Carlos III, Universidad Autonoma de Barcelona, Barcelona, Spain.
  • Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
  • Applied Science Research Center, Applied Science Private University, Amman, Jordan.

ORCID-Profile: Tatyana Kushner, Mohamed El-Kassas, Yusuf Yilmaz, Yuichiro Eguchi, Ming-Lung Yu, Stuart C Gordon, Lindsey Hiebert-Suwondo, Linda Henry, Zobair M Younossi

Förderung

  • Global NASH/MASH
  • Global Liver Council
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Kushner, T., Buti, M., El-Kassas, M., Yilmaz, Y., Takahashi, H., Eguchi, Y., Roberts, S. K., Chan, W. K., Yu, M. L., Ocama, P., Khaderi, S., Wungjiranirun, M., Jacobson, I. M., Gordon, S. C., Nicolas, A., Ward, J., Gupta, N., Hiebert-Suwondo, L., Reynoso, S., …, & Global Liver Council (2026). Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey. Liver International, 46(5). https://doi.org/10.1111/liv.70619

Vancouver

Kushner T, Buti M, El-Kassas M, Yilmaz Y, Takahashi H, Eguchi Y, et al. Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey. Liver International. 2026;46(5). doi:10.1111/liv.70619

BibTeX
@article{Kushner2026,
  author = {Kushner, Tatyana and Buti, Maria and El-Kassas, Mohamed and Yilmaz, Yusuf and Takahashi, Hirokazu and Eguchi, Yuichiro and Roberts, Stuart K and Chan, Wah-Kheong and Yu, Ming-Lung and Ocama, Ponsiano and Khaderi, Saira and Wungjiranirun, Manida and Jacobson, Ira M and Gordon, Stuart C and Nicolas, Aina and Ward, John and Gupta, Neil and Hiebert-Suwondo, Lindsey and Reynoso, Sheila and Henry, Linda and Stepanova, Maria and Papatheodoridis, George and Younossi, Zobair M and Global Liver Council, Global Liver Council},
  title = {Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {5},
  doi = {10.1111/liv.70619}
}
Kostenlos starten →